ATRA - アタラ・バイオセラピュ―ティクス （Atara Biotherapeutics Inc.）

Atara has a cell therapy with a unique approach based on a novel allogeneic Epstein-Barr virus T-cell platform. Read what could be next for ATRA after a challenging year.

During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 1.1 million, with the beta value of the company hitting 0.91. At the end of the trading day, the stock’s price was $5.04, reflecting an intraday loss of -7.69% or -$0.42. The 52-week high for the ATRA share is $16.07, that puts it down … Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Jumped 43.59% Over A Month – Is There Any Hope Of A Gain? Read More »

Atara Biotherapeutics Inc earnings missed by $0.17, revenue fell short of estimates

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Wednesday reported a loss of…

Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023 Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel® ATA188 Phase 2 EMBOLD Study Primary Data… | February 8, 2023

During the last session, Atara Biotherapeutics Inc. (NASDAQ:ATRA)’s traded shares were 1.99 million, with the beta value of the company hitting 0.97. At the end of the trading day, the stock’s price was $4.70. The 52-week high for the ATRA share is $20.04, that puts it down -326.38 from that peak though still a striking … Will Atara Biotherapeutics Inc. (NASDAQ: ATRA) Stock Boom Or Bust From Here? Read More »

Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Wednesday, September 14, with the stock price up by 2.84% to the previous day’s close as strong demand from buyers drove the stock to $4.70. Actively observing the price movement in the last trading, the stock closed the session at $4.57, falling within a range of … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Stock A New Investor Should Consider Now? Read More »

Atara Biotherapeutics Inc. (NASDAQ:ATRA) closed Friday at $4.82 per share, up from $4.75 a day earlier. While Atara Biotherapeutics Inc. has overperformed by 1.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATRA fell by -68.02%, with highs and lows ranging from $20.04 to $2.83, whereas […]

The trading price of Atara Biotherapeutics Inc. (NASDAQ:ATRA) closed lower on Monday, August 22, closing at $4.18, -6.07% lower than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $4.16 and $4.51. In examining the 52-week price action we see that the stock hit a 52-week … Atara Biotherapeutics Inc. (NASDAQ: ATRA) Can Raise Stock -6.07% More Read More »

An investigation for investors in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares over potential securities laws violations by Atara Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -- 08/18/2022 -- Atara Biotherapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Atara Biotherapeutics, Inc. (NASDAQ: ATRA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Atara Biotherapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made. San Francisco, CA based Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. On November 4, 2021, Atara Biotherapeutics, Inc issued a press release touting its T cell immunotherapy product candidate, ATA188.

In last trading session, Atara Biotherapeutics Inc. (NASDAQ:ATRA) saw 0.55 million shares changing hands with its beta currently measuring 1.76. Company’s recent per share price level of $8.76 trading at -$0.31 or -3.42% at ring of the bell on the day assigns it a market valuation of $797.51M. That closing price of ATRA’s stock is … Atara Biotherapeutics Inc. (NASDAQ:ATRA) Stock Plunged -44.42% So Far In 2022, What Analysts Expect Next? Read More »

Atara Biotherapeutics (ATRA) appoints biopharma executive Charlene Banard as its new chief technical officer. Banard comes to Atara from Novartis, where, as Global Head,…

Facility acquisition includes 134 employees in manufacturing and quality positions Facility acquisition includes 134 employees in manufacturing and quality positions

Atara Biotherapeutics Inc. (NASDAQ:ATRA) shares, rose in value on Friday, 03/11/22, with the stock price down by -2.59% to the previous day’s close as strong demand from buyers drove the stock to $9.02. Actively observing the price movement in the last trading, the stock closed the session at $9.26, falling within a range of $9.00 … Is Atara Biotherapeutics Inc. (NASDAQ: ATRA) A Good Pick For New Investors Now? Read More »